Disease · MONDO_0000496
hemorrhagic cystitis
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. hemorrhagic cystitis. Diseases, record MONDO_0000496. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0000496
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Highest stage of its drugs
- Phase 3, for 1 of its 6 drugs, from ClinicalTrials.gov and TTD
- Open Targets
Drugs6
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| POSOLEUCEL | CHEMBL4594340 | Cell | Phase 3 | ClinicalTrials.gov and TTD | 3 | 1 | 1 | Drugs and targets |
| CIDOFOVIR | CHEMBL5314375 | Small molecule | Phase 2 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| CHLOROPHYLLIN COPPER COMPLEX | CHEMBL2108919 | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets | |
| TACROLIMUS | CHEMBL3989887 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| PROBENECID | CHEMBL897 | Small molecule | Phase 1 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| BUSULFAN | CHEMBL820 | Small molecule | Unknown | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
Targets4
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| FKBP1A | Peptidyl-prolyl cis-trans isomerase FKBP1A | 1 | FK506-binding protein 1A inhibitor | Phase 2 | https://conductscience.org/library/genes/2280 | Drugs and targets |
| SLC22A11 | Solute carrier family 22 member 11 | 1 | Solute carrier family 22 member 11 inhibitor | Phase 1 | https://conductscience.org/library/genes/55867 | Drugs and targets |
| SLC22A6 | Solute carrier family 22 member 6 | 1 | Solute carrier family 22 member 6 inhibitor | Phase 1 | https://conductscience.org/library/genes/9356 | Drugs and targets |
| SLC22A8 | Organic anion transporter 3 | 1 | Solute carrier family 22 member 8 inhibitor | Phase 1 | https://conductscience.org/library/genes/9376 | Drugs and targets |
Trials7
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04390113 | Study to Evaluate Viralym-M (ALVR105) for the Treatment of Virus-Associated Hemorrhagic Cystitis (HC) | Phase 3 | 97 | 2024-05-14 | BK Virus Infection, Hemorrhagic Cystitis | POSOLEUCEL | Its record names the disease | ClinicalTrials.gov |
| NCT04786002 | Target Busulfan Exposure in Children With HSCT in China | 500 | Hematopoietic Stem Cell Transplantation | BUSULFAN | Its record names the disease | ClinicalTrials.gov | ||
| NCT01295645 | Cidofovir Versus Best Supportive Care for Hemorrhagic Cystitis | Phase 2 | 27 | Transplantation Infection | CIDOFOVIR | Its record names the disease | ClinicalTrials.gov | |
| NCT05348239 | Chlorophyllin Tablets for Urinary Bleeding Following Radiation Therapy for Cancers of Pelvic Organs | Phase 2 | 24 | Hemorrhagic Cystitis | CHLOROPHYLLIN COPPER COMPLEX | Its record names the disease | ClinicalTrials.gov | |
| NCT03129126 | The Safety, Tolerability and Efficacy of LP-10 in Subjects With Refractory Moderate to Severe Hemorrhagic Cystitis | Phase 2 | 13 | Hemorrhagic Cystitis | TACROLIMUS | Its record names the disease | ClinicalTrials.gov | |
| NCT01816646 | Intravesical Cidofovir for Hemorrhagic Cystitis | Phase 1 | 6 | Blood And Marrow Transplantation | CIDOFOVIR, PROBENECID | Its record names the disease | ClinicalTrials.gov | |
| NCT00956176 | Cidofovir Instillation in Hematopoietic Stem Cell Transplant (HSCT) Recipients With Hemorrhagic Cystitis | Not applicable | 0 | Cystitis, Bladder Diseases | CIDOFOVIR | Its record names the disease | ClinicalTrials.gov |
Comparisons in its trials4
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Posoleucel (ALVR105) vs Placebo: deaths from any cause | 2 of 57 | 1 of 40 | 97 | NCT04390113 | Trial comparisons |
| Posoleucel (ALVR105) vs Placebo: Number of Participants With Treatment Emergent Acute Graft Versus Host Disease (GVHD) | 11 of 57 | 9 of 39 | 96 | NCT04390113 | Trial comparisons |
| Posoleucel (ALVR105) vs Placebo: Number of Participants With Treatment Emergent Cytokine Release Syndrome (CRS) | 1 of 57 | 0 of 39 | 96 | NCT04390113 | Trial comparisons |
| Posoleucel (ALVR105) vs Placebo: serious adverse events | 28 of 57 | 19 of 39 | 96 | NCT04390113 | Trial comparisons |
Papers from its trials2
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0000496
GET https://conductscience.org/api/diseases/v1/MONDO_0000496/drugs